UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC APP 68658/2024

Dec 30, 2024·EP2501384: METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY

Case details
Status
Case Closed
Action
Generic
Category
Document Access (RoP262)
Parties
Claimants
Reps: Phillip Rektorschek
Respondents
Reps: Gregory Bacon (Bristows LLP); Wim Maas (Taylor Wessing)
Division
Milan CD
Judges
Technology
Organic Chemistry
Language
English
First decided
Feb 3, 2025
Decisions
  • 2025-02-03
    DismissedApplication RoP262.1 (b)

    Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP (separate application number for the same underlying proceedings UPC_CFI_698/2024, Milan Central Division). Outcome identical to companion order: STADAPHARM's request to access documents was dismissed; NOVARTIS's request for legal cost compensation was dismissed. This appears to be the same decision issued under a different application reference number.

    Legal issues:Public access to court documents R.262.1(b) RoPPrimary purpose of access requestIntegrity of proceedingsR.4.1 RoP digital signature requirements
Documents
Document titleDatePublic
Exhibit TW 0 - Payment Court Fees2025-02-19Not public
Order 3 Februar 20252025-02-19Not public
2025 02 18 - Appeal_signed2025-02-19Not public
Exhibit TW 22025-02-19Not public
Appeal Pleading2025-02-19Not public
Exhibit TW 32025-02-19Not public
Exhibit TW 2a2025-02-19Not public
Outcome of the Order2025-02-03Not public
ORDER 3rd February2025-02-03Public
Outcome of the Order2025-02-03Not public
ORDER 3rd February2025-02-03Public
Template-Order2025-02-03Not public
Receipt2025-01-24Not public
Reply by Applicant2025-01-24Not public
Exhibit TW 12025-01-24Not public
Novartis reply to Stadapharm R.262(1)b request2025-01-17Not public
Comments2025-01-17Not public
ORDER 02.01.252025-01-02Not public
Template-Order2025-01-02Not public
2024 12 30 - Request RoP 262(1)b_signed2024-12-30Not public